Erectile dysfunction decisions — 2025

The appeal for service connection for erectile dysfunction was dismissed as it had already been awarded, and the appeals for a higher rating and earlier effective date for hypertension were denied. The claim for sleep apnea was remanded.

The veteran's appeal requests were not timely filed, and good cause was not shown to accept the late filings.

The Board granted service connection for cervical strain, left and right hip disabilities (post-traumatic arthritis), erectile dysfunction, and SMC based on loss of use of a creative organ with an effective date of September 28, 2012. Other claims were denied.

The Board granted a 70 percent rating for PTSD with unspecified depressive disorder, panic disorder, and excoriation disorder with alcohol use disorder but denied other claims including erectile dysfunction, chronic sinusitis, allergic rhinitis, dermatitis, GERD, OSA, CFS, and IBS.

The Board granted service connection for tinnitus and denied it for bilateral hearing loss. Other claims were remanded for further development.

The Board remands the claims for service connection and TDIU due to a pre-decisional duty to assist error regarding SSA records.

The Board granted a rating of 20 percent, but no higher, for erectile dysfunction and remanded the claim for a rating in excess of 20 percent for slight lumbar scoliosis with IVDS.

The Board remands the claim for service connection for erectile dysfunction with hypogonadism to the AOJ for an adequate medical examination and opinions.

The Board denied service connection for bilateral hearing loss, and remanded the claims for erectile dysfunction and obstructive sleep apnea.

The Board remands the claims for service connection for chronic kidney disease, hypertension, supraventricular arrhythmias, erectile dysfunction and coronary artery disease to correct a pre-decisional duty to assist error.

The Board granted service connection for erectile dysfunction, secondary to the Veteran's service-connected sarcoidosis.

The Board denied entitlement to a total disability rating based on individual unemployability due to service-connected disability prior to April 28, 2020, and denied earlier effective dates for DEA benefits. The Board granted restoration of a 50 percent disability rating for migraines effective July 1, 2023, but denied ratings in excess of the assigned levels for other conditions.

The Board granted service connection for bilateral pes planus and plantar fasciitis, an initial rating of 50 percent for migraine headaches, but denied service connection for obstructive sleep apnea (OSA), traumatic brain injury (TBI), a compensable rating for erectile dysfunction, and a higher rating for posttraumatic stress disorder (PTSD).

The Board denied service connection for left and right shoulder disabilities, multi-joint arthritis, and erectile dysfunction as the evidence did not support a finding that these conditions were related to the Veteran's service.

The Board granted service connection for tension headaches, obstructive sleep apnea, and erectile dysfunction, with an initial rating of 50 percent for the tension headaches.

The Board granted an effective date of April 26, 2018, for the award of service connection for multiple sclerosis and associated conditions, chronic migraine headaches, and trigeminal neuralgia.

The Board denied service connection for diabetes mellitus, type II and related conditions due to a lack of evidence linking the Veteran's current disabilities to his active service or toxic exposure at Camp Lejeune.

The Board denied service connection for a low back disability, erectile dysfunction, and an acquired psychiatric disorder as the evidence did not support a finding that these conditions were related to active service or secondary to any service-connected condition.

The Board remands the claims for service connection for erectile dysfunction and migraines, to include as secondary to service-connected disabilities, due to pre-decisional duty to assist errors.

The Board remands the claims for service connection for asthma, erectile dysfunction, and chronic fatigue syndrome as further development is needed.